Incyte Corporation
Incyte Reports 2024 Q4 and Full Year Financial Results and Provides 2025 Guidance
Summary
Incyte Corporation announced its 2024 fourth quarter and full-year financial results, reporting a 15% year-over-year increase in total revenues to $4.2 billion. Key highlights include 11% growth in Jakafi net revenues and 48% growth in Opzelura net revenues. The company provided 2025 financial guidance, anticipating revenue contributions from new product launches and pivotal study readouts. Incyte expects 2025 to be a year of defining catalysts with four launches, four pivotal study readouts, three Phase 3 study initiations, and seven proof of concept study readouts.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement